New hope for dialysis patients: drug trial targets dangerous phosphorus levels
NCT ID NCT07285291
First seen Jan 11, 2026 · Last updated Apr 25, 2026 · Updated 15 times
Summary
This study tests an experimental drug called TS-172 in 100 adults on hemodialysis who have high phosphorus levels (hyperphosphatemia). Participants will take TS-172 or a placebo alongside their current phosphate binder medication. The goal is to see if TS-172 helps more patients reach safe phosphorus levels, which is important for managing kidney disease long-term.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERPHOSPHATEMIA PATIENTS ON HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Taisho Pharmaceutical Co., Ltd selected site
RECRUITINGTokyo, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.